Rafia Hussaini, MD
Internal Medicine · Newark, NJNPI 1194902643
Payments from drug & device makers
Across 129 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$635
- Dexcom, Inc.$447
- Johnson & Johnson$168
- Amgen$166
- Novartis$117
- Lilly USA, LLC$100
- plus $555 from 13 others
What the payments were for
- Food & beverage$2,187100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $635 |
| Dexcom, Inc. | 21 | $447 |
| Johnson & Johnson(2 entities) | 6 | $168 |
| Amgen | 12 | $166 |
| Novartis | 9 | $117 |
| Lilly USA, LLC | 7 | $100 |
| Gilead | 5 | $73 |
| E.r. Squibb & Sons, L.L.C. | 6 | $71 |
| Merck | 5 | $64 |
| GSK | 4 | $61 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $43 |
| Amarin Pharma, Inc. | 3 | $42 |
| AstraZeneca | 3 | $42 |
| Boehringer Ingelheim | 3 | $40 |
| Bayer | 2 | $38 |
| Pfizer | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$119
How this compares
$2,187 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 111 | $139,670 |
| OzempicSemaglutide | 93 | $116,687 |
| TrulicityDulaglutide | 26 | $55,944 |
| EliquisApixaban | 34 | $40,682 |
| RybelsusSemaglutide | 19 | $40,674 |
| TradjentaLinagliptin | 15 | $19,168 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $15,470 |
| FarxigaDapagliflozin Propanediol | 20 | $15,030 |
| MyrbetriqMirabegron | 12 | $14,843 |
| Spiriva RespimatTiotropium Bromide | 18 | $10,731 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,304 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $9,043 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $6,659 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 32 | $6,103 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $5,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $40 | $169,570144 claims |
| Novo NordiskOzempic, Rybelsus | $635 | $157,361112 claims |
| Lilly USA, LLCTrulicity | $100 | $55,94426 claims |
| PfizerEliquis | $32 | $40,68234 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Shingrix | $61 | $23,75061 claims |
| AstraZenecaFarxiga, Symbicort | $42 | $19,66238 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $14,84312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Newark
- Helio PedroNewark$1.8M
- Amesika NyakuNewark$127K
- Christian EngellNewark$53K
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.